1 21 4

Shareholder Tools

Home Investor Relations

Investor Relations

  1. Chart
  2. Quote
Stock price graph
+ 0.28
Day High:
Day Low:
4:00 PM ET on Nov 26, 2014

Delayed at least 20 minutes.
Provided by eSignal.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. MacroGenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. The combination of MacroGenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.

Corporate Fact Sheet

Corporate Fact Sheet

PDF  Corporate Fact Sheet

View all »   RSSRecent Releases

Nov 12, 2014
MacroGenics to Present at the Stifel 2014 Healthcare Conference

Nov 11, 2014
MacroGenics Provides Update on Corporate Progress and Third Quarter 2014 Financial Results

View all »Events & Presentations

Dec 6, 2014 at 5:30 PM ET
Pre-clinical Data to be Presented at ASH 2014 Annual Meeting
New DART® Candidate: MGD011 (CD19 x CD3) Pre-clinical Data will be Highlighted